Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors

Experimental Neurology

Volumn 159, Issue 1, 1999, Pages 47-64

  Mandel, Ronald J ^a   Rendahl, K G ^b   Snyder, Richard O ^b   Leff, Stuart E ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CELL GENESYS INC   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Apomorphine; Dopamine; Neostriatum; Substantia nigra; Tetrahydrobiopterin

Indexed keywords

LEVODOPA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; DYSKINESIA; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HALLUCINATION; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; NEOSTRIATUM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRUS RECOMBINANT;

EID: 0032847711     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7159     Document Type: Article

References (161)

1. Afione S. A., Conrad C. K., Kearns W. G., Chunduru S., Adams R., Reynolds T. C., Guggino W. B., Cutting G. R., Carter B. J., Flotte T. R. In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 70:1996;3235-3241.
2. Anastasiadis P. Z., Kuhn D. M., Blitz J., Imerman B. A., Louie M. C., Levine R. A. Regulation of tyrosine hydroxylase and tetrahydrobiopterin biosynthetic enzymes in PC12 cells by NGF, EGF and IFN-gamma. Brain Res. 713:1996;125-133.
3. Anton R., Kordower J. H., Maidment N. T., Manaster J. S., Kane D. J., Rabizadeh S., Schueller S. B., Yang J., Edwards R. H., Markham C. H., Bredesen D. E. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp. Neurol. 127:1994;207-218.
4. Asin K. E., Bednarz L., Nikkel A., Perner R. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa. J. Pharmacol. Exp. Ther. 273:1995;1483-1490.
5. Bankiewicz K., Mandel R. J., Sofroniew M. V. Trophism, transplantation, and animal models of Parkinson's disease. Exp. Neurol. 124:1993;140-149.
6. Bankiewicz K. S., Bringas J. R., Mclaughlin W., Pivirotto P., Hundal R., Yang B., Emborg M. E., Nagy D. Application of gene therapy for Parkinson's disease: Nonhuman primate experience. Adv. Pharmacol. 42:1998;801-806.
7. Bankiewicz K. S., Leff S. E., Nagy D., Jungles S., Rokovich J., Spratt K., Cohen L., Libonati M., Snyder R. O., Mandel R. J. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp. Neurol. 144:1997;147-156.
8. Barker J. E., Strangward H. M., Brand M. P., Hurst R. D., Land J. M., Clark J. B., Heales S. J. R. Increased inducible nitric oxide synthase protein but limited nitric oxide formation occurs in astrocytes of the hph-1 (tetrahydrobiopterin deficient) mouse. Brain Res. 804:1998;1-6.
9. Barker R., Dunnett S. B. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Exp. Brain Res. 101:1994;365-374.
10. Bartlett J. S., Samulski R. J., McCown T. J. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9:1998;1181-1186.
11. Bencsics C., Wachtel S. R., Milstien S., Hatakeyama K., Becker J. B., Kang U. J. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of l-dopa by primary fibroblasts. J. Neurosci. 16:1996;4449-4456.
12. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20:1973;415-455.
13. Betz A. L., Shakui P., Davidson B. L. Gene transfer to rodent brain with recombinant adenoviral vectors: Effects of infusion parameters, infectious titer, and virus concentration on transduction volume. Exp. Neurol. 150:1998;136-142.
14. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.-J., Mallet J., Horellou P. Intrastriatal injection of an adenoviral vector expression glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA. 94:1997;8818-8823.
15. Björklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4:1997;186-200.
16. Blömer U., Naldini L., Kafri T., Trono D., Verma I. M., Gage F. H. Highly efficient and sustained gene transfer in adult neurons and lentivirus vector. J. Virol. 71:1997;6641-6649.
17. Bohl D., Salvetti A., Moullier P., Heard J. M. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood. 92:1998;1512-1517.
18. Bohn, M. C., and D. L. Choi-Lundberg. 1998. Gene therapies for Parkinson's disease. Pages 377-395 in E. A. Chiocca and X. O. Breakfield, Eds., Gene Therapy for Neurological Disorders and Brain Tumors. Humana Press, Totowa, NJ.
19. Bowers W. J., Howard D. F., Federoff H. J. Gene therapeutic strategies for neuroprotection: Implications for Parkinson's disease. Exp. Neurol. 144:1997;58-68.
20. Bravi D., Mouradian M. M., Roberts J. W., Davis T. L., Sohn Y. H., Chase T. N. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms. Ann. Neurol. 36:1994;27-31.
21. Byrnes A. P., MacLaren R. E., Charlton H. M. Immunological instability of persistent adenovirus vectors in the brain: Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J. Neurosci. 16:1996;3045-3055.
22. Byrnes A. P., Rusby J. E., Wood M. J. A., Charlton H. M. Adenovirus gene transfer causes inflammation in the brain. Neuroscience. 66:1995;1015-1024.
23. Byrnes A. P., Wood M. J., Charlton H. M. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther. 3:1996;644-651.
24. Calne D. B., Sandler M. l-Dopa and parkinsonism. Nature. 226:1970;21-24.
25. Carey R. J., Pinheirocarrera M., Dai H. L., Tomaz C., Huston J. P. l-Dopa and psychosis: Evidence for l-dopa-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol. Psychiatry. 38:1995;669-676.
26. Carlsson A. The "on-off" effect. Adv. Neurol. 5:1974;367-368.
27. Chamberlin N. L., Du B., de Lacalle S., Saper C. B. Recombinant adeno-associated virus vector: Use for transgene expression and anterograde tract tracing in the CNS. Brain Res. 793:1998;169-175.
28. Chang J. W., Wachtel S. R., Young D., Kang U. J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience. 468:1999;617-628.
29. Chase T. N., Baronti F., Fabbrini G., Heuser I. J., Juncos J. L., Mouradian M. M. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 39:1989;7-10.
30. Chase T. N., Engber T. M., Mouradian M. M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology. 44:1994;S15-S18.
31. Chase T. N., Mouradian M. M., Engber T. M. Motor response complications and the function of striatal efferent systems. Neurology. 43:1993;23-27.
32. Choi-Lundberg D. L., Lin Q., Chang L.-N., Chiang L., Hay C. M., Mohajeri H., Davidson B. L., Bohn M. C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 275:1997;838-841.
33. Conway J. E., Zolotukhin S., Muzyczka N., Hayward G. S., Byrne B. J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71:1997;8780-8789.
34. Corti O., Sabaté O., Horellou P., Colin P., Dumas S., Buchet D., Buc-Caron M.-H., Mallet J. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat. Biotechnol. 17:1999;349-354.
35. Davidson B. L., Allen E. D., Kozarsky K. F., Wilson J. M., Roessler B. J. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat. Genet. 3:1993;219-223.
36. Davidson B. L., Bohn M. C. Recombinant adenovirus: A gene transfer vector for study and treatment of CNS diseases. Exp. Neurol. 144:1997;125-130.
37. Dull T., Zufferey R., Kelly M., Mandel R. J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:1998;8463-8471.
38. During M. J., Leone P. Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. Clin. Neurosci. 3:1996;292-300.
39. During M. J., Naegele J. R., O'Malley K. L., Geller A. I. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science. 266:1994;1399-1403.
40. Engber T. M., Susel Z., Juncos J. L., Chase T. N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168:1989;291-298.
41. Fabbrini G., Juncos J., Mouradian M. M., Cerrati C., Chase T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann. Neurol. 21:1987;370-376.
42. Fabbrini G., Mouradian M. M., Juncos J. L., Schlegel J., Mohr E., Chase T. N. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I. Ann. Neurol. 24:1988;366-371.
43. Fan D. S., Ogawa M., Fujimoto K. I., Ikeguchi K., Ogasawara Y., Urabe M., Nishizawa M., Nakano I., Yoshida M., Nagatsu I., Ichinose H., Nagatsu T., Kurtzman G. J., Ozawa K. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9:1998;2527-2535.
44. Fink D. J., Poliani P. L., Oligino T., Krisky D. M., Goins W. F., Glorioso J. C. Development of an HSV-based vector for the treatment of Parkinson's disease. Exp. Neurol. 144:1997;103-121.
45. Fisher L. J., Jinnah H. A., Kale L. C., Higgins G. A., Gage F. H. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce l-dopa. Neuron. 6:1991;371-380.
46. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Kriek E., Qi J.-X., Lome T., Zhang Y.-B., Snyder J. A., Wells T. H., Olson R. L., Thompson L., Mazziotta J. C., Huang S. C., Grafton S. T., Brooks D., Sawle G., Schroter G., Ansari A. A. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinsons disease. N. Engl. J. Med. 327:1992;1549-1555.
47. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Kriek E., Qui J.-X., Lone T., Zhang Y.-B., Snyder J. A., Wells T. H., Ramig L. O., Thompson L., Mazziotta J. C., Huang S. C., Grafton S. T., Brooks D., Sawle G., Schroter G., Ansari A. A. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327:1992;1549-1555.
48. Gage F. H., Wolff J. A., Rosenberg M. B., Xu L., Yee J.-K., Shults C., Friedmann T. Grafting genetically modified cells to the brain: Possibilities for the future. Neuroscience. 23:1987;795-807.
49. Gerfen C. R., McGinty J. F., Young W. S. Dopamine differentially regulates dynorphin, substance-P, and enkephalin expression in striatal neurons - In situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031.
50. 3H flunitrazepam. Neuroscience. 57:1993;673-681.
51. Goetz C. G., Tanner C. M., Klawans H. L. Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psychiat. 139:1982;494-497.
52. Goldstein M., Deutch A. Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6:1992;2413-2421.
53. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5557.
54. Grisso J. A., Kelsey J. L., Strom B. L. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N. Engl. J. Med. 324:1991;1326-1331.
55. Hefti F., Enz A., Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Neuropharmacology. 24:1985;19-23.
56. Herzog R. W., Hagstrom J. N., Kung S. H., Tai S. J., Wilson J. M., Fisher K. J., High K. A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA. 94:1997;5804-5809.
57. Horellou P., Vigne E., Castel M. N., Barneoud P., Colin P., Perricaudet M., Delaere P., Mallet J. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport. 6:1994;49-53.
58. Hornykiewicz O. Parkinson's disease: From brain homogenate to treatment. Fed. Proc. 32:1973;183-190.
59. Ichinose H., Nagatsu T. Molecular genetics of hereditary dystonia - Mutations in the GTP cyclohydrolase I gene. Brain Res. Bull. 43:1997;35-38.
60. Ichinose H., Ohye T., Segawa M., Nomura Y., Endo K., Tanaka H., Tsuji S., Fujita K., Nagatsu T. GTP cyclohydrolase I gene in hereditary progressive dystonia with marked diurnal fluctuation. Neurosci. Lett. 196:1995;5-8.
61. Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M., Nomura Y., Endo K., Tanaka H., Tsuji S., Fujita K., Nagatsu T. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet. 8:1994;236-242.
62. Isacson O. Behavioral effects and gene delivery in a rat model of Parkinson's disease. Science. 269:1995;856-857.
63. Jooss K., Yang Y., Fisher K. J., Wilson J. M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72:1998;4212-4223.
64. Kajiwara K., Byrnes A. P., Charlton H. M., Wood M. J., Wood K. J. Immune responses to adenoviral vectors during gene transfer in the brain. Hum. Gene Ther. 8:1997;253-265.
65. Kaplitt M. G., Leone P., Samulski R. J., Xiao X., Pfaff D. W., O'Malley K. L., During M. J. Long term gene expression and phenotypic correction using adeno associated virus vectors in the mammalian brain. Nat. Genet. 8:1994;148-153.
66. Katusic Z. S., Stelter A., Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;27-32.
67. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277.
68. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318:1988;876-880.
69. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H., Bujard H. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA. 93:1996;10933-10938.
70. Klein R. L., Meyer E. M., Peel A. L., Zolotukhin S., Meyers C., Muzyczka N., King M. A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150:1998;183-194.
71. Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J. G., Mufson E. J., Sanberg P. R., Hauser R. A., Smith D. A., Nauert G. M., Perl D. P., Olanow C. W. Neuropathological evidence of graft survival and striatal reinnervation after transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332:1995;1118-1124.
72. Kordower J. H., Rosenstein J. M., Collier T. J., Burke M. A., Chen E. Y., Li J. M., Martel L., Levey A. E., Mufson E. J., Freeman T. B., Olanow C. W. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370:1996;203-230.
73. Leff S. E., Rendahl K. G., Spratt S. K., Kang U. J., Mandel R. J. In vivol-dopa production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts requires co-expression of GTP-cyclohydrolase I with tyrosine hydroxylase. Exp. Neurol. 151:1998;249-264.
74. Leff S. E., Spratt S. K., Snyder R. O., Mandel R. J. Restoration of striatal l-aromatic amino acid decarboxylase activity using recombinant adeno-associated virus in an animal model of Parkinson's disease. Neuroscience. 92:1999;187-198.
75. Lentz S. I., Kapatos G. Tetrahydrobiopterin biosynthesis in the rat brain: Heterogeneity of GTP cyclohydrolase I mRNA expression in monoamine-containing neurons. Neurochem. Int. 28:1996;569-582.
76. Levine R. A., Kuhn D. M., Lovenberg W. The regional distribution of hydroxylase cofactor in rat brain. J. Neurochem. 32:1979;1575-1578.
77. Levine R. A., Miller L. P., Lovenberg W. Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science. 214:1981;919-921.
78. Lieberman D. M., Laske D. W., Morrison P. F., Bankiewicz K. S., Oldfield E. H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82:1995;1021-1029.
79. Lindner M. D., Plone M. A., Francis J. M., Emerich D. F. Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral sinimet. Brain Res. Bull. 39:1996;367-372.
80. Lindvall O. Neural transplantation. Cell Transplant. 4:1995;393-400.
81. Lindvall O., Widner H., Rehncrona S., Brundin P., Odin P., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Bjorklund A., Marsden C. D. Transplantation of fetal dopamine neurons in Parkinson's disease: One year clinical and neurophysiological observations in patients with putaminal implants. Ann. Neurol. 31:1992;155-165.
82. Lloyd K. G. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv. Exp. Med. Biol. 90:1977;255-266.
83. Ludecke B., Dworniczak B., Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum. Genet. 95:1995;123-125.
84. Lundberg C., Horellou P., Mallet J., Bjorklund A. Generation of dopa-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: In vitro characterization and in vivo effects in the rat Parkinson model. Exp. Neurol. 139:1996;39-53.
85. Mandel R. J., Brundin P., Björklund A. The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur. J. Neurosci. 2:1990;888-894.
86. Mandel R. J., Gage F. H., Clevenger D. G., Spratt S. K., Snyder R. O., Leff S. E. Nerve growth factor expressed in the medial septum following in vivo gene delivery using recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp. Neurol. 155:1999;59-64.
87. Mandel, R. J., S. Hardy, R. O. Snyder, L. Naldini, and S. E. Leff. 1999. Intracerebral gene transfer using viral vectors. Pages 103-130 in S. B. Dunnett, A. Bolton, and G. Baker, Eds., NeuroMethods. Humana Press, Totowa, NJ.
88. Mandel R. J., Rendahl K. G., Spratt K. S., Snyder R. O., Cohen L. K., Leff S. E. Characterization of intrastriatal recombinant adeno-associated virus mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydroxylase I in a rat model of Parkinson's disease. J. Neurosci. 18:1998;4271-4284.
89. Mandel R. J., Spratt S. K., Snyder R. O., Leff S. E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA. 94:1997;14083-14088.
90. Mandel R. J., Wilcox R. E., Randall P. K. Behavioral quantification of striatal dopaminergic supersensitivity after bilateral 6-hydroxydopamine lesions in the mouse. Pharmacol. Biochem. Behav. 41:1992;343-347.
91. Manning W. C., Zhou S., Bland M. P., Escobedo J. A., Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9:1998;477-485.
92. Marsden, C. D., J. D. Parkes, and N. Quinn. 1982. Fluctuations of disability in Parkinson's disease - Clinical aspects. Pages 96-122 in C. D. Marsden and S. Fahn, Eds., Movement Disorders. Butterworth Scientific, London.
93. Matsuo A., Tooyama I., Isobe S., Oomura Y., Akiguchi I., Hanai K., Kimura J., Kimura H. Immunohistochemical localization in the rat brain of an epitope corresponding to the fibroblast growth factor receptor-1. Neuroscience. 60:1994;49-66.
94. McCown T. J., Xiao X., Li J., Breese G. R., Samulski R. J. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:1996;99-107.
95. Melamed E., Hefti F. Mechanism of action of short- and long-term l-dopa treatment in Parkinsonism: Role of the surviving nigrostriatal dopaminergic neurons. Hassler R. G., Christ J. F. Advances in Neurology. 1984;149-157 Raven Press, New York.
96. Mouradian M. M., Chase T. N. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin. Neuropharmacol. 11:1988;378-385.
97. Mouradian M. M., Heuser I. J. E., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25:1989;523-526.
98. Mouradian M. M., Juncos J. L., Fabbrini G., Schlegel J., Bartko J. J., Chase T. N. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part II. Ann. Neurol. 24:1988;372-378.
99. Muzyczka N. Use of adeno associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:1992;97-129.
100. Muzyczka N., Samulski R. J., Hermonat P., Srivastava A., Berns K. I. The genetics of adeno-associated virus. Adv. Exp. Med. Biol. 179:1984;151-161.
101. Nagatsu T., Levitt M., Udenfriend S. Tyrosine hydroxylase. J. Biol. Chem. 239:1964;2910-2917.
102. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267.
103. Neve R. L., Geller A. I. A defective herpes simplex virus vector system for gene delivery into the brain: Comparison with alternative gene delivery systems and usefulness for gene therapy. Clin. Neurosci. 3:1996;262-267.
104. Nichol C. A., Smith G. K., Duch D. S. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. Annu. Rev. Biochem. 54:1985;729-764.
105. No D., Yao T.-P., Evans R. M. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA. 93:1996;3346-3351.
106. Nutt J. G., Holford N. H. G. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann. Neurol. 39:1996;561-573.
107. Nyberg P., Nordberg A., Wester P., Winblad B. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's disease. Neurochem. Pathol. 1:1983;193-202.
108. Obeso J. A., Grandas F., Herrero M. T., Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci. 6:1994;889-897.
109. Oertel, W, and, N. P. Quinn, Parkinsonism, T. Brandt, L. R. Caplan, J. Dichgans, H. C. Diener, and C. Kennard, Editors. Pages, 715, - 772, in, Neurological Disorders: Course and Treatment, San Diego, CA, Academic Press, Inc. 1996.
110. Olson L., Strömberg I., Herrera-Marschitz M., Ungerstedt U., Ebendal T. Adrenal medullary tissue grafted to the dopamine-denervated rat striatum: Histochemical and functional effects of additions of nerve growth factor. Björklund A., Stenevi U. Neural Grafting in the Mammalian CNS. 1985;505-518 Elsevier, Amsterdam.
111. Pearce R. K., Jackson M., Smith L., Jenner P., Marsden C. D. Chronic l-dopa administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10:1995;731-740.
112. Peel A. L., Zolotukhin S., Schrimsher G. W., Muzyczka N., Reier P. J. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4:1997;16-24.
113. Pickles R. J., McCarty D., Matsui H., Hart P. J., Randell S. H., Boucher R. C. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72:1998;6014-6023.
114. Piedimonte G., Pickles R. J., Lehmann J. R., McCarty D., Costa D. L., Boucher R. C. Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. Am. J. Respir. Cell Mol. Biol. 16:1997;250-258.
115. Piedra P. A., Poveda G. A., Ramsey B., McCoy K., Hiatt P. W. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors. Pediatrics. 101:1998;1013-1019.
116. Qing K., Mah C., Hansen J., Zhou S., Dwarki V., Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:1999;71-77.
117. Rajput A. H., Gibb W. R., Zhong X. H., Shannak K. S., Kish S., Chang L. G., Hornykiewicz O. Dopa-responsive dystonia: Pathological and biochemical observations in a case [see comments]. Ann. Neurol. 35:1994;396-402.
118. Reiner A., Anderson K. D. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: Conclusions based on recent findings. Brain Res. Rev. 15:1991;251-265.
119. Rendahl K. G., Leff S. E., Otten G. R., Spratt S. K., Bohl D., Roey M. V., Donahue B. A., Cohen L. K., Mandel R. J., Danos O., Snyder R. O. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat. Biotechnol. 16:1998;757-761.
120. Rivera V. M., Clackson T., Natesan S., Pollock R., Amara J. F., Keenan T., Magari S. R., Phillips T., Courage N. L., Cerasoli F. Jr., Holt D. A., Gilman M. A humanized system for pharmacologic control of gene expression. Nat. Med. 2:1996;1028-1032.
121. Sakai N., Kaufman S., Milstien S. Parallel induction of nitric oxide and tetrahydrobiopterin synthesis by cytokines in rat glial cells. J. Neurochem. 65:1995;895-902.
122. Schallert T., Hall S. 'Disengage' sensorimotor deficit following apparent recovery from unilateral dopamine depletion. Behav. Brain Res. 30:1988;15-24.
123. Schallert T., Kozlowski D. A., Humm J. L., Cocke R. R. Use-dependent structural events in recovery of function. Adv. Neurol. 73:1997;229-238.
124. Schott K., Gutlich M., Ziegler I. Induction of GTP-cyclohydrolase I mRNA expression by lectin activation and interferon-gamma treatment in human cells associated with the immune response. J. Cell Physiol. 156:1993;12-16.
125. Schuh L. A., Bennett J. P. Suppression of dyskinesias in advanced Parkinson's disease. 1. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology. 43:1993;1545-1550.
126. Snyder R. O., Miao C. H., Patijn G. A., Spratt S. K., Danos O., Gown A. M., Winther B., Meuse L., Cohen L. K., Thompson A. R., Kay M. A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16:1997;270-276.
127. Snyder R. O., Spratt S. K., Lagarde C., Bohl D., Kaspar B., Sloan B., Cohen L. K., Danos O. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8:1997;1891-1900.
128. Snyder R. O., Xiao X., Samulski R. J. Production of recombinant adeno-associated viral vectors. Dracopoli N., Haines J., Krof B., Moir D., Morton C., Seidman C., Seidman J., Smith D. Current Protocols in Human Genetics. 1996;1-24 Wiley, New York.
129. Sohn Y. H., Metman L. V., Bravi D., Linfante I., Aotsuka A., Mouradian M. M., Chase T. N. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinsons disease. Neurology. 44:1994;755-757.
130. Spencer D. D., Robbins R. J., Naftolin F., Marek K. L., Vollmer T., Leranth C., Roth R. H., Price L. H., Gjedde A., Bunney B. S., Sass K. J., Elsworth J. D., Kier E. L., Makuch R., Hoffer P. B., Redmond D. E. Jr. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327:1992;1541-1548.
131. Suhr S. T., Gil E. B., Senut M. C., Gage F. H. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc. Natl. Acad. Sci. USA. 95:1998;7999-8004.
132. Summerford C., Bartlett J. S., Samulski R. J. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:1999;78-82.
133. Summerford C., Samulski R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1998;1438-1445.
134. Szczypka M. S., Mandel R. J., Donahue B. A., Snyder R. O., Leff S. E., Palmiter R. D. Viral gene therapy selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron. 22:1999;167-178.
135. Togari A., Arai M., Mogi M., Kondo A., Nagatsu T. Coexpression of GTP cyclohydrolase I and inducible nitric oxide synthase mRNAs in mouse osteoblastic cells activated by proinflammatory cytokines. FEBS Lett. 428:1998;212-216.
136. Tropepe V., Craig C. G., Morshead C. M., van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. J. Neurosci. 17:1997;7850-7859.
137. Uchida K., Ishii A., Kaneda N., Toya S., Nagatsu T., Kohsaka S. Tetrahydrobiopterin-dependent production of l-dopa in NRK fibroblasts transfected with tyrosine hydroxylase cDNA: Future use for intracerebral grafting. Neurosci. Lett. 109:1990;282-286.
138. Uchida K., Tsuzaki N., Nagatsu T., Kohsaka S. Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA. Dev. Neurosci. 14:1992;173-180.
139. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;95-126.
140. van Ginkel F. W., McGhee J. R., Liu C., Simecka J. W., Yamamoto M., Frizzell R. A., Sorscher E. J., Kiyono H., Pascual D. W. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J. Immunol. 159:1997;685-693.
141. Verma I. M., Somia N. Gene therapy - Promises, problems and prospects [news]. Nature. 389:1997;239-242.
142. Wagner J. A., Reynolds T., Moran M. L., Moss R. B., Wine J. J., Flotte T. R., Gardner P. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus [letter]. Lancet. 351:1998;1702-1703.
143. Walter R., Linscheid P., Blau N., Kierat L., Schaffner A., Schoedon G. Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. Immunol. Lett. 60:1998;13-17.
144. Weiner N., Molinoff P. B. Catecholamines. Siegel G., Agranoff B., Albers R. W., Molinoff P. Basic Neurochemistry. 1989;233-251 Raven Press, New York.
145. Werner E. R., Werner-Felmayer G., Fuchs D., Hausen A., Reibnegger G., Yim J. J., Pfeiderer W., Wachter H. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. J. Biol. Chem. 265:1990;3189-3192.
146. Widner H., Tetrud J., Rehncrona S. T., Snow B., Brundin P., Gustavii B., Björklund A., Lindvall O., Langston J. W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327:1992;1556-1563.
147. Wolff J. A., Fisher L. J., Xu L., Jinnah H. A., Langlais P. J., Iuvone P. M., O'Malley K. L., Rosenberg M. B., Shimohama S., Friedmann T., Gage F. H. Grafting fibroblasts genetically modified to produce l-dopa in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 86:1989;9011-9014.
148. Wood M. J., Byrnes A. P., Kaplitt M. G., Pfaff D. W., Rabkin S. D., Charlton H. M. Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: Implications for gene targeting. Exp. Neurol. 130:1994;127-140.
149. Wood M. J., Byrnes A. P., Pfaff D. W., Rabkin S. D., Charlton H. M. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther. 1:1994;283-291.
150. Wood M. J., Byrnes A. P., Rabkin S. D., Pfaff D. W., Charlton H. M. Immunological consequences of HSV-1-mediated gene transfer into the CNS. Gene Ther. 1:1994;S82.
151. Wood M. J., Charlton H. M., Wood K. J., Kajiwara K., Byrnes A. P. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci. 19:1996;497-501.
152. Wu D. K., Cepko C. L. The stability of endogenous tyrosine hydroxylase protein in PC-12 cells differs from that expressed in mouse fibroblasts by gene transfer. J. Neurochem. 62:1994;863-872.
153. Xiao X., Li J., Samulski R. J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:1996;8098-8108.
154. Xiao X., Li J., Samulski R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:1998;2224-2232.
155. Yahr M. D. Parkinsons disease - The l-dopa era. Narabayashi H., Nagatsu T., Yanagisawa N., Mizuno Y. Advances in Neurology. 1993;11-17 Raven Press, New York.
156. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gonczol E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA. 91:1994;4407-4411.
157. Ye X., Rivera V. M., Zoltick P., Cerasoli F. Jr., Schnell M. A., Gao G., Hughes J. V., Gilman M., Wilson J. M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 283:1999;88-91.
158. Zhou Q. Y., Palmiter R. D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell. 83:1995;1197-1209.
159. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. Trends Neurosci. 13:1990;290-296.
160. Zufferey R., Dull T., Mandel R. J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:1998;9873-9880.
161. Zufferey R., Nagy D., Mandel R. J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:1997;871-875.